Department of Cell Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Nat Cell Biol. 2024 Jan;26(1):124-137. doi: 10.1038/s41556-023-01314-6. Epub 2024 Jan 2.
The gut microbiota play a pivotal role in human health. Emerging evidence indicates that gut microbes participate in the progression of tumorigenesis through the generation of carcinogenic metabolites. However, the underlying molecular mechanism is largely unknown. In the present study we show that a tryptophan metabolite derived from Peptostreptococcus anaerobius, trans-3-indoleacrylic acid (IDA), facilitates colorectal carcinogenesis. Mechanistically, IDA acts as an endogenous ligand of an aryl hydrocarbon receptor (AHR) to transcriptionally upregulate the expression of ALDH1A3 (aldehyde dehydrogenase 1 family member A3), which utilizes retinal as a substrate to generate NADH, essential for ferroptosis-suppressor protein 1(FSP1)-mediated synthesis of reduced coenzyme Q10. Loss of AHR or ALDH1A3 largely abrogates IDA-promoted tumour development both in vitro and in vivo. It is interesting that P. anaerobius is significantly enriched in patients with colorectal cancer (CRC). IDA treatment or implantation of P. anaerobius promotes CRC progression in both xenograft model and Apc mice. Together, our findings demonstrate that targeting the IDA-AHR-ALDH1A3 axis should be promising for ferroptosis-related CRC treatment.
肠道微生物群在人类健康中起着关键作用。新出现的证据表明,肠道微生物通过产生致癌代谢物参与肿瘤发生的进展。然而,其潜在的分子机制在很大程度上尚不清楚。在本研究中,我们表明源自厌氧消化链球菌的色氨酸代谢物反式-3-吲哚丙烯酸(IDA)促进结直肠肿瘤发生。从机制上讲,IDA 作为芳烃受体(AHR)的内源性配体,转录上调 ALDH1A3(醛脱氢酶 1 家族成员 A3)的表达,ALDH1A3 利用视黄醛作为底物生成 NADH,这是铁死亡抑制蛋白 1(FSP1)介导的还原辅酶 Q10 合成所必需的。在体外和体内,缺失 AHR 或 ALDH1A3 均可显著阻断 IDA 促进的肿瘤发生。有趣的是,厌氧消化链球菌在结直肠癌(CRC)患者中明显富集。IDA 处理或厌氧消化链球菌的植入均可促进异种移植模型和 Apc 小鼠的 CRC 进展。总之,我们的研究结果表明,靶向 IDA-AHR-ALDH1A3 轴可能是治疗与铁死亡相关的 CRC 的一种有前途的方法。
Cancer Res. 2024-3-15
J Cancer Res Clin Oncol. 2024-4-20
J Cancer Res Clin Oncol. 2023-1
Compr Physiol. 2025-8
Cell Death Discov. 2025-8-1
Front Physiol. 2025-7-10
Nat Cell Biol. 2023-9
Nat Cell Biol. 2023-9
Nat Cell Biol. 2023-8
Cancer Discov. 2022-7-6
Mol Cell. 2022-3-3